Sutro Biopharma (STRO) Net Income towards Common Stockholders (2017 - 2025)

Sutro Biopharma has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$46.8 million for Q4 2025.

• Net Income towards Common Stockholders for Q4 2025 came in at -$46.8 million, down 130.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$180.4 million (down 7418.17% YoY), and the FY2025 annual result was -$191.1 million, down 7861.62% from the prior year.
• Net Income towards Common Stockholders came in at -$46.8 million for Q4 2025 at Sutro Biopharma, up from -$56.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $152.6 million in Q4 2024 to a low of -$65.3 million in Q1 2025.
• The 5-year median for Net Income towards Common Stockholders is -$38.3 million (2021), against an average of -$25.2 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 322.82% in 2022 and soared 391.29% in 2024, its largest moves.
• Sutro Biopharma's Net Income towards Common Stockholders stood at -$38.1 million in 2021, then gained by 9.26% to -$34.6 million in 2022, then surged by 189.8% to $31.1 million in 2023, then jumped by 391.29% to $152.6 million in 2024, then tumbled by 130.64% to -$46.8 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$46.8 million (Q4 2025), -$56.9 million (Q3 2025), and -$11.5 million (Q2 2025), per Business Quant data.